Spyryx is developing inhaled peptides designed to potently degrade ENaC (epithelial sodium channels), which play a role in mucus dehydration and reduced airway clearance.
In California, Hispanic patients with cystic fibrosis were three times as likely to die from the disease as their non-Hispanic counterparts, despite similar access to specialty care.
According to new research, the 5-year survival rate for Canadians with cystic fibrosis who have received a lung transplant is 67% and half of those who have had transplants live beyond 10 years.
Parion Sciences will receive $80 million in funding from Vertex Pharmaceuticals in a collaboration to develop a novel CF medication.
The development award will help support a Phase 2 clinical trial of the Celtaxsys's lead development candidate, a once daily, oral anti-inflammatory drug CTX-4430 in adults with cystic fibrosis.
A combination of the drugs Kalydeco (ivacaftor) and lumacaftor successfully treated the defective CF protein, improved lung function, and helped reduce pulmonary exacerbations by 40%.
Spyryx Biosciences, Inc, has raised $18 million in financing, which will be used to develop therapies to treat respiratory conditions including cystic fibrosis (CF) and chronic obstructive pulmonary disease (COPD).
Vertex's investigational drug Orkambi (lumacaftor/ivacaftor) could potentially treat 8,500 Americans with cystic fibrosis aged 12 and older with two copies of the F508del mutation.
The Food and Drug Administration (FDA) is questioning whether an experimental combination therapy for cystic fibrosis (CF) from Vertex Pharmaceuticals has any added benefits over Kalydeco.
The European Commission has granted orphan medicinal product designation to AIT-CF, a cystic fibrosis treatment from Advanced Inhalation Therapies Ltd.
Corbus, a small biopharmaceutical company, received $5 million from the Cystic Fibrosis Foundation last month to develop the drug, Resunab.
Nick Talbot, a 39-year-old man with cystic fibrosis, will attempt to be the first person with this condition to climb Mount Everest.
Cystic Fibrosis Foundation Therapeutics has provided a $14M grant to Genzyme to develop therapy options for cystic fibrosis patients with the common mutation F508del.
In a recent clinical study, use of AffloVest, a portable High Frequency Chest Wall Oscillation (HFCWO) vest, showed lung function improvements in a group of teens with cystic fibrosis.
New research from Prime Therapeutics indicates that new treatments for cystic fibrosis targeting gene mutations will notably increase health care costs.
A recent report on future trends in cystic fibrosis (CF) predicts a nearly 80% increase in the number of CF patients living into adulthood by the year 2025.
A New Mexico student collaborated with a laboratory at MIT to develop an automated cough monitor that aims to alert parents of children afflicted with cystic fibrosis to a coughing spasm.
New research from the Washington University School of Medicine reveals insight into possibly counteracting inappropriate mucus production in conditions such as asthma and chronic obstructive pulmonary disease (COPD).
Publicly insured Americans who undergo lung transplantation for cystic fibrosis fare markedly worse in the long run than privately insured Americans.
Sollpura (liprotamase) is an investigational enzyme therapy appropriated for those with lower levels of digestive enzyme, or Exocrine Pancreatic Insufficiency (EPI) caused by several diseases, including cystic fibrosis.